ELEXACAFTOR + TEZACAFTOR + IVACAFTOR
Information current as at: 1 June 2025
PBAC meeting date: May 2021
Submission Details
- Brand name:
-
- Trikafta®
- Pharmaceutical company:
- Vertex Pharmaceuticals (Australia) Pty Ltd
- Condition/indication:
(therapeutic use) -
- Cystic fibrosis
- PBAC Submission type:
- New listing (Matters outstanding)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – May 2021
- Related medicines:
Progress Details
-
Submission received for: - May 2021 PBAC meeting
-
Opportunity for consumer comment: - --
-
PBAC meeting: - Held on 07/05/2021
-
PBAC outcome published: - Deferred (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a385
Page last updated: 02 May 2024